Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.
CBL-514 selectively induces apoptosis of fat cells, reducing subcutaneous and visceral fat volume by 10.45% and 22.21% respectively in phase 2 clinical trials. The drug was well-tolerated with mostly mild-to-moderate injection-site reactions.
Real-world study data from Germany, Austria and Luxembourg show that GLP-1 receptor agonist drugs improve weight (37% reduction ≥ 5%), blood sugar control (glycaemic improvement) and systolic blood pressure in children and adolescents with type 2 diabetes. These benefits remained significant after adjustment for other factors.
Researchers found trevogrumab significantly reduced lean mass loss by 50% when used with semaglutide. Participants who received trevogrumab experienced a mean increase in lean mass of +0.4%, while those who received placebo experienced a mean decrease of -2.4%.
The ACHIEVE-4 study shows orforglipron pills offer superior weight loss and blood sugar control compared to insulin glargine, but with a higher gastrointestinal adverse event rate. Non-inferiority for cardiovascular safety and superiority for weight reduction were demonstrated.
The phase 2b study evaluates the safety and efficacy of eloralintide in combination with tirzepatide, resulting in substantial weight loss and improvements in blood sugar control. The study demonstrated substantial weight loss and reduction in glycated haemoglobin (HbA1c) across different dosing combinations.
Petrelintide, an amylin-based obesity drug, shows significant weight loss of over 10% in a phase 2 trial, with fewer gastrointestinal side effects compared to GLP-1 drugs. The study also reveals improvements in key cardiovascular risk factors, such as blood pressure and lipid parameters.
Retatrutide demonstrates substantial weight loss and improved blood sugar control in adults with overweight and type 2 diabetes, with 47% of participants losing at least 20% of their starting weight. The treatment also improves cardiometabolic risk factors and reduces inflammation.
Women are more likely to experience weight loss and improved blood sugar control with GLP-1 RAs, but face higher rates of side effects and unequal access to treatment worldwide. Extensive research is needed to address these disparities and optimize treatment for women in various domains.
A systematic review of 43,000 women with diabetes exposed to GLP-1 RAs found no significant associations with preterm birth, stillbirth, or neonatal death, but evidence gaps remain for early pregnancy loss and postpartum use. Further research is needed to address these gaps and provide clearer evidence for women with diabetes
A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.
A Danish study suggests that GLP-1 drugs could protect heart health in millions of people with overweight. The research found that individuals with a BMI of 25-26.9 and high remnant cholesterol and/or low-grade inflammation have a similar risk of coronary heart disease as those eligible for GLP-1 RAs for weight loss.
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
The new guidelines, developed by leading experts, focus on improving sepsis care by strengthening systems for diagnosis, treatment, prevention, and quality improvement. Emerging technologies, such as next-generation diagnostics and artificial intelligence, are also being explored to enhance sepsis care.
Young people with HIV who receive injections every eight weeks manage their condition better than those taking daily tablets, according to a study published in The Lancet. The injections suppressed the virus more effectively, with only 1% of participants experiencing viral rebound, compared to 6% on daily tablets.
Researchers are evaluating the health and economic consequences of subpar buprenorphine dosing among Medicaid-covered pregnant women to improve maternal and infant outcomes. Data suggest that up to 90% of pregnant women require higher doses of buprenorphine.
UVA researchers will use AI-assisted tools to develop a digital model showing how hormone differences impact medication effectiveness in women. The model will be tested on bacterial vaginosis and metabolic dysfunction-associated steatotic liver disease, with the goal of creating personalized predictions and more targeted drug therapies.
A study published in JAMA found that intravenous loberamisal increased the proportion of patients with acute ischemic stroke achieving full functional outcomes at 90 days. The treatment resulted in a higher proportion of patients regaining full functional abilities compared to placebo.
University of California, Davis researchers successfully synthesized new compounds with reduced hallucinogenic and cardiotoxic effects, identifying one compound with antipsychotic-like effects. By systematically deconstructing LSD, they uncovered the importance of the phenethylamine-like traits in producing hallucinogenic effects.
Scientists at MUSC Hollings Cancer Center discovered a protein called lysyl oxidase that helps triple-negative breast cancer cells survive. Blocking LOX creates a weakness, which can be exploited with a second drug to block tumor growth without chemotherapy.
A $3.3 million NIH grant will support a five-year study on opioid treatment during breastfeeding, aiming to improve drug safety for lactating mothers. The researchers will develop a cell-based assay and use physiologically based pharmacokinetic models to predict drug levels in mothers and infants.
The updated guideline recommends routine obesity screening, comprehensive lifestyle intervention, and individualized use of medications and endoscopic and surgical procedures. Obesity should be treated as a chronic disease requiring longitudinal, flexible care pathways.
A recent study by the Ethiopian Public Health Institute and the JAMA Network has identified emerging drug and diagnostic resistance variants as contributing factors to Ethiopia's malaria resurgence. The study highlights the need for continued monitoring and adaptation of treatment strategies to combat the growing malaria epidemic.
A comparative study of 11,681 US cancer clinical trials reveals that industry-sponsored trials focus on single-agent drug therapies, while federally sponsored trials evaluate nontreatment interventions and rare cancer therapies. The study highlights the differences in trial design and objectives between industry and federal funding.
Researchers have identified several existing TGA-approved medicines that could slow brain damage in children with Sanfilippo syndrome, a devastating childhood dementia. The study used lab-grown brain cells and AI to rapidly test approved drugs and pinpoint those that improve brain cell health.
Researchers discovered that psilocybin reorganizes brain patterns, revealing hidden order, with stronger reorganisation linked to positive psychological changes. The study's findings have implications for developing therapies to improve clarity and psychological flexibility.
Surzen Biotherapeutics aims to develop effective pain relief without severe side effects by targeting opioid receptor pathways differently. The company plans to use peptides to block dimerization, reducing tolerance and improving efficacy.
Researchers at Virginia Tech developed a wearable microneedle patch called the iNal patch that can detect fentanyl in the body and automatically release naloxone to reverse an opioid overdose. The patch uses porous silica nanoparticles loaded with naloxone, which is released when fentanyl levels are detected.
A new study found a 17-fold increase in intravenous iron use among Australian women aged 18-44, with over 82 million dollars spent on the treatment. The study highlights the growing awareness of iron deficiency's impact on women's health, but also raises questions about access to equitable treatment.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
Researchers highlight unanticipated benefits of GLP-1 medications, including reduced inflammation and lower risk of certain cardiovascular and musculoskeletal conditions. However, questions remain about lean body mass and nutritional health following weight loss associated with these medications.
By focusing on the specific regions of antibodies responsible for recognizing disease targets, the AI model improved binding affinity prediction and required fewer computational resources. This approach is similar to human-language AI models, where smaller domain-specific models trained on high-quality data can outperform larger ones.
A retrospective cohort study found that patients treated with aripiprazole had a lower risk of hyponatremia than those on olanzapine. This association could inform clinical decision-making for high-risk patients, despite residual confounding considerations.
New research at Aston University shows that mānuka honey's effectiveness against disease-causing bacteria cannot be attributed solely to its sugar content and methylglyoxal levels. The study identified additional bioactive compounds responsible for the antimicrobial activity, which may lead to the development of more effective honey-de...
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
Researchers developed a method to predict how different types of breast cancer will respond to treatment using lab-grown mini tumors. The organoids mimicked a tumor's response to treatment and identified candidate combination therapies for cancers that don't respond to standard treatment.
A new study found that patients from wealthier European countries tend to start biologic treatments earlier but stop or switch treatment earlier, experiencing lower disease activity. The study highlights the importance of ensuring timely and equitable access to effective treatment for patients with PsA and axSpA.
SourceElsevier·JournalAnnals of the Rheumatic Diseases·TypeData/statistical analysis·DateAug 11, 2026
A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...
A noninferiority randomized clinical trial found that an alternative first-line regimen containing doravirine, lamivudine, and tenofovir disoproxil fumarate produced less weight gain than a combination of dolutegravir, emtricitabine, and tenofovir alafenamide. The regimen was noninferior for viral suppression at 48 weeks.
Hepatic encephalopathy recurrence can be reduced through education on precipitants correction and pharmacotherapy with lactulose and rifaximin. Nutritional support with protein-rich diets improves QOL and reduces episodes.
A new study from the University of Colorado Anschutz found that oral semaglutide reduced heavy drinking and alcohol-related harm in adults with Alcohol Use Disorder. The medication, commonly used for diabetes and weight loss, showed consistent reductions in harmful real-world drinking behavior.
A new pan-European study identified the psychological and contextual factors that shape decision-making among healthcare professionals. The findings provide important insights into how behaviour change frameworks could support the uptake of new treatments, with the strongest lever being to shift intention to prescribe.
A Phase 2 clinical trial shows that a THC/CBD combination significantly reduces agitation in hospice-eligible people with dementia. The study, conducted across multiple US sites, achieved its primary and key secondary endpoints, demonstrating the efficacy of this treatment approach for end-of-life agitation.
A new study in the Canadian Journal of Cardiology predicts that generic semaglutide will dramatically increase cost-effectiveness and health system affordability for patients with type 2 diabetes and high cardiorenal risk. The estimated annual cost of providing GLP-1RAs to all indicated patients would be $3.35 to $5.31 billion at pre-g...
Repeatedly losing and gaining weight accelerates muscle loss in middle-aged people, as found in new UC San Francisco research. The study analyzed MRI scans of 1,433 participants and found that those with fluctuating weights lost nearly four times as much thigh muscle over four years.
Clesrovimab, a long-acting monoclonal antibody, demonstrates safety and efficacy in reducing severe respiratory syncytial virus (RSV) disease in high-risk infants over two RSV seasons. The study supports the use of clesrovimab in children at increased risk for severe RSV disease during their second season.
The Herbularyo card game combines Filipino folk healing traditions with organic chemistry, teaching students about medicinal plants and their therapeutic properties. The game has been shown to be an effective learning tool, increasing student engagement and understanding of the subject.
A recent study published by the University of Sydney found that dexamphetamine and methylphenidate are equally effective in treating ADHD in children, with no significant differences in symptom improvement. However, children taking dexamphetamine experienced greater weight loss compared to those taking methylphenidate.
The ECOG-ACRIN ENDURANCE trial found that indefinite lenalidomide maintenance had no survival benefit and more toxicity compared to stopping treatment after 2 years in patients not undergoing a stem cell transplant. The study suggests that fixed duration treatment can significantly reduce healthcare costs.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Incorporating structured, video-enhanced feedback into training programs halves prescribing errors by newly qualified doctors. This approach closes the performance gap between novice and experienced prescribers, demonstrates cost-effectiveness and scalability.
The European Association for the Study of Obesity, dietitian societies, and other organizations have issued a consensus statement on the use of incretin drugs in obesity therapy. Key findings include the importance of medical nutrition therapy delivered by registered dietitians to complement incretin-based therapies. The statement also...
A new study published in the Canadian Medical Association Journal found that older adults discharged from hospital with a new prescription for sedatives are at increased risk of falls, further need for acute hospital care, and death within 30 days. The study looked at over 1.86 million adults aged 66 years and older and found a 20% hig...
Lecanemab is approved to treat early Alzheimer's disease, but its clinical benefits are modest. The treatment carries serious adverse effects and requires resource-intensive monitoring with MRI scans.
A new prodrug and localized drug delivery platform have been developed by researchers to selectively target cancer cells. The platform uses carbamate masking of the 4-anilinoquinazoline hinge nitrogen to modulate exposure and enable controlled activation of EGFR-TKIs in tumour microenvironments.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Researchers found that women who used hormonal birth control in young adulthood had larger brain volumes in regions vital to memory and cognition. Estrogen exposure throughout life may be beneficial for brain health, particularly in reducing dementia risk. The study suggests hormone therapy during menopause may also support brain health.
Researchers found that over-the-counter probiotics contain only 36 unique species of bacteria, with most common species being forms of Lactobacillus. The analysis suggests a lack of consistency in the combination of species used to support gut health and vaginal health claims.
Researchers at Rutgers University link GLP-1 medication use to reduced violent behavior, finding a substantial weakening of the relationship between impulsivity and aggression among users compared to non-users. The study suggests these medications may work like cognitive behavioral therapy, reducing impulsive actions.